No Carolina / New York / Florida        Ph: 561.316.3330

MediPines Releases Scientific Paper on COVID-19 Respiratory Monitoring

What To Know

  • MediPines notes in an effort to support healthcare providers facing massive healthcare burdens due to the current respiratory challenges caused by COVID-19, MediPines has released a timely scientific discussion on oxygen saturation versus pulmonary gas exchange as a respiratory monitoring imperative for COVID-19 patients.
  • “Consistent with our founding mission of advancing respiratory medicine, MediPines is committed to sharing our scientific discoveries and medical insights with the medical community, with the latest breakthrough news and advancements in respiratory medicine to improve patient care.

July 15, 2020

MediPines notes in an effort to support healthcare providers facing massive healthcare burdens due to the current respiratory challenges caused by COVID-19, MediPines has released a timely scientific discussion on oxygen saturation versus pulmonary gas exchange as a respiratory monitoring imperative for COVID-19 patients.

MediPines reports patients with COVID-19 do not always present with traditional signs and symptoms of respiratory distress, making it difficult for healthcare providers to rely on traditional tools such as pulse oximetry. Pulse oximeters provide a rapid estimate of arterial oxygenation saturation; however, saturation alone is insufficient for the assessment of respiratory impairment as it does not “see” pulmonary gas exchange in patients with chronic lung diseases, such as COPD, or in patients with infectious respiratory diseases like COVID-19.

Amidst this global crisis, innovative hospitals across the United States and Canada are leveraging a new respiratory monitoring system, the MediPines AGM100®. The AGM100 is significantly impacting hospital providers and COVID-19 triage centers as it provides rapid, accurate pulmonary gas exchange measurements. Pulmonary gas exchange is the primary function of the lungs. In time-sensitive respiratory cases, rapid assessment results can have a significant impact on patient care decisions and outcomes.

“Consistent with our founding mission of advancing respiratory medicine, MediPines is committed to sharing our scientific discoveries and medical insights with the medical community, with the latest breakthrough news and advancements in respiratory medicine to improve patient care. There is a need for more and ongoing research and scientific discoveries in the respiratory field,” stated MediPines CEO, Steve Lee.

Latest

CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Unlocking New Hope: Alzheimer’s Patients Join Amyloid-Targeting Therapy Study

0
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

0
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

0
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

0
The research, presented at the American Society of Interventional Pain Physicians (ASIPP) Annual Meeting, included a registrational Phase 3 trial and an integrated safety analysis of six clinical studies, as well as a real-world analysis of current treatment options and gaps in the clinical management of patients with newly-diagnosed LDH.

Reports breaking medical device and biotechnololgy news

About
Press Releases
Advertise
Privacy
Cookie Policy

Contact:  561.316.3330

Offices: No. Carolina / New York

© Medical Device News Magazine 2024

By using this website you agree to accept Medical Device News Magazine Privacy Policy